Ad
PSTV - PLUS THERAPEUTICS Stock Trading
About | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
Quote | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
| Last: | $ |
|---|---|
| Change Percent: | 2.29% |
| Open: | $2.15 |
| Close: | $2.23 |
| High: | $2.29 |
| Low: | $2.15 |
| Volume: | 51,911 |
| Last Trade Date Time: | 02/12/2020 04:43:17 pm |
News | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
-
AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced th...
-
2023-11-22 16:28:09 ET More on Plus Therapeutics Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript Plus Therapeutics climbs on FDA orphan drug tag for radiotherapy Biocept gains on licensing pact with Plus Therapeutics for cancer test Seeking Al...
Message Board Posts | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
| Subject | By | Source | When |
|---|---|---|---|
| The company more than likely will announce a | Sierra20 | investorshub | 04/20/2023 4:52:51 AM |
| NEWS -- Plus Therapeutics Completes Enrollment of the | Paulness | investorshub | 04/19/2023 11:51:05 AM |
| NEWS -- Plus Therapeutics to Participate in Panel | Paulness | investorshub | 04/19/2023 12:00:25 AM |
| NEWS -- Plus Therapeutics Completes Phase 1/Part A | Paulness | investorshub | 04/18/2023 11:33:10 AM |
| May announce reverse split on 4/20? | Sierra20 | investorshub | 04/12/2023 1:57:16 PM |
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
Ad
-
AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compa...
-
AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced th...
-
Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive Median progression free survival (mPFS) is 11 mon...